Research programme: Alzheimer's disease therapeutics transdermal - Corium International
Latest Information Update: 01 Sep 2015
At a glance
- Originator Corium International
- Class Amines; Organic bridged compounds; Small molecules
- Mechanism of Action NMDA receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Alzheimer's disease